Our products

NeuroSTAT® — Treatment for traumatic brain injury

As things currently stand, there is nothing doctors can do to stop secondary cell death following severe traumatic brain injury. NeuroVive has in-licensed a lipid emulsion and developed NeuroSTAT®, a patented, fully finished product comprising the active agent cyclosporin-A and a carrier medium that is free of cremophor and alcohol.

Protecting nerve cells

Cyclosporin-A strengthens mitochondrial membranes by binding to and inhibiting the protein cyclophilin-D. This allows the mitochondria to take up and store much more calcium without being damaged, ensuring their ability to continue to produce energy and reducing the risk of nerve-cell death. The cells of the brain are protected by maintaining their energy supply.

Traumatic brain injury

Traumatic brain injuries open the blood–brain barrier. This makes it possible to reach the areas of the brain where the need is greatest by administering cyclosporine-A intravenously to patients.

Immunosuppressive application

As an alternative to existing pharmaceuticals, NeuroSTAT® can also be used to suppress the immune defenses for indications such as organ transplantation.

CicloMulsion® — Treatment for Reperfusion Injury during myocardial infarction

An estimated 500,000 Americans have an ST-elevation myocardial infarction each year. Myocardial reperfusion (abruptly re-establishing blood flow through the blocked artery) can result in additional injury that can account for up to 50% of the final size of the infarct. Widespread mitochondrial collapse caused by reperfusion injury can be reduced through the application of cyclosporine.

CicloMulsion® is the cardiac version of NeuroSTAT® and strengthens mitochondrial membranes during myocardial infarction by binding to and inhibiting the protein cyclophilin-D’s action in the biochemical imbalances resulting from reperfusion. This allows the mitochondria to take up and store much more calcium without being damaged, ensuring their ability to continue to produce energy and reducing the risk of additional cardiac cell death and reperfusion injury. A small-group study published in The New England Journal of Medicine (2008) found a 40% reduction in infarct size with the application of cyclosporine-A (CicloMulsion®). An editorial in the same issue called for a large-scale study to confirm the extent of cyclosporine’s ability to protect heart tissue. An investigator-initiated Phase III clinical study of CicloMulsion® with 1,000 patients was initiated in Europe in April 2011.